According to the GuruFocus All-in-One Screener the following five companies reported the largest insider buys last week. These are the largest insider buys in terms of transaction amount, level of insider making buys and number of insiders buying.
Tessera Technologies (TSRA)
Over the past week there have been three directors of Tessera making notable buys back into the company. These three insiders made five separate buys, adding 628,500 shares to their stake.
Director Peter Feld made the largest transaction by making three buys and purchasing a total of 625,000. He purchased these shares in the price range of $18.44 to $18.93 per share. The price per share has dropped approximately -1.32%. Feld now owns 4.7 million shares of Tessera stock.
Director George Riedel bought 1,500 shares at $18.82 per share. This transaction cost the director a total of $28,230. Since his buy, the price per share has dropped approximately -1.7%. Riedel now owns at least 20,066 shares of company stock.
Director George Cwynar added 2,000 shares to his holdings at an average price of $18.49 per share. The transaction cost the director a total of $36,980. Since his buy, the price per share has increased 0.05%. Cwynar now holds on to 20,226 shares of company stock.
[/url]
Tessera Technologies is a holding company with operating subsidiaries in two segments: Intellectual Property and DigitalOptics.
Tessera Technologies’ historical revenue and net income:
The analysis on Tessera Technologies reports that the company’s P/E ratio is at a 10-year high, its revenue has been in decline over the past five years, its dividend yield is at a 2-year high and that the company has no debt.
Tessera Technologies has a market cap of $996.9 million. Its shares are currently trading at a P/E ratio of 166.00, a P/S ratio of 4.70 and a P/B ratio of 1.70. The company’s dividend yield is currently at 2.20%.
There are currently four gurus that hold a position in TSRA.
Valeant Pharmaceuticals (VRX)
During the past week there have been two insiders that have made notable buys into Valeant Pharmaceuticals.
Director Ronald Farmer bought 2,500 shares on Aug. 28. The director bought these shares at an average price of $102.36 per share for a total transaction amount of $255,900. Since this buy, the price per share has dropped approximately -3.33%. Farmer now holds on to at least 26,057 shares of company stock.
Executive VP, General Counsel and Corporate Secretary Robert Chai-Onn purchased 5,032 shares on Aug. 23. The VP purchased these shares at $99.30 per share for a total transaction amount of $499,678. Since his buy the price per share has dropped approximately -0.35%. Chai-Onn now holds on to a total of 188,277 shares of company stock.
These buys came as the price per share hit a 10-year high.
Valeant Pharmaceuticals is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.
Valeant Pharmaceuticals’ historical revenue and net income:
The analysis on Valeant reports that the price is near a 10-year high, the P/E ratio is at a 10-year high, the company has issued $6.5 billion of debt over the past three years and that the company’s asset growth is faster than its revenue growth.
Valeant Pharmaceuticals has a market cap of $32.81 billion. Its shares are currently trading at around $98.68 with a P/E ratio of 1041.60, a P/S ratio of 7.50 and a P/B ratio of 5.20. The company had an annual average earnings growth of 4.2% over the past ten years.
There are currently 18 gurus that hold a position in Valeant Pharmaceuticals.
Multi-Color Corporation (LABL)
Over the past week two directors made buys into Multi-Color Corporation.
Director Ari Benacerraf bought 12,000 shares on Aug. 23. The director bought these shares at a price of $32.48 per share for a total transaction amount of $389,760. Since his buy, the price per share has dropped -3.33%.
Director Simon Roberts added a much smaller 2,400 shares to his stake at an average cost of $32.42 per share. This cost him a total of $77,808. Since his buy, the price per share has dropped -3.15%.
[/url]
These insider buys were made as the company’s price hit a 10-year high.
The Company provides a wide range of products for the packaging needs of its customers and is a producer of high quality pressure sensitive, in-mold and heat transfer labels, and a major manufacturer of glue-applied and shrink sleeve labels.
Multi-Color’s historical revenue and net income:
The analysis on Multi-Color reports that company has issued $320.952 million of debt in the past three years, they have shown predictable revenue and earnings growth, the operating margin is expanding and their price is nearing a 10-year high.
The Peter Lynch Chart suggests that the company is currently overvalued:
Multi-Color has a market cap of $514.4 million. Its shares are currently trading at around $31.40 with a P/E ratio of 17.70, a P/S ratio of 0.80 and a P/B ratio of 1.90. The company had an annual average earnings growth of 14.3% over the past ten years.
GuruFocus rated Multi-Color the business predictability rank of 4-star.
Joel Greenblatt and Jim Simons hold a position in Multi-Color Corporation.
Independent Bank Group (IBTX)
Over the past week Independent Bank Group reported eight insider buys as coming from six different insiders. These buys come as the share price has taken a slight drop.
The insiders making buys consisted of Director William Fair, Director Stacy Smith, Executive VP and CFO Michelle Hickrox, Vice Chairman and CLO Brian Hobart, Director Brian Aynesworth III and President and COO Torry Berntsen.
These insiders bought a total of 28,718 shares of IBTX in the price range of $34.02 to $35.07, with an estimated average price of $34.49 per share. Since these buys the price per share has increased approximately 2.1%.
Director William Fair bought a total of 14,192 shares at an average price of $34.52 per share. These buys cost him a total of $491,960. Since his buys, the share price has increased
Independent Bank Group is a holding company for Independent Bank which provides a wide range of relationship-driven commercial banking products and services tailored to meet the needs of businesses, professionals and individuals. The company operates offices in Dallas/Fort Worth and the greater Austin area.
Independent Bank’s historical revenue and net income:
The company recently announced that they would be acquiring Live Oak State Bank.
The analysis on Independent Bank Group reports that the price is nearing a 52-week high and that the company has enough cash to cover all of its debt.
Independent Bank Group has a market cap of $411.8 million. Its shares are currently trading at around $34.12 with a P/E ratio of 13.90, a P/S ratio of 3.90 and a P/B ratio of 1.90.
Chuck Royce holds a stake in Independent Bank Group.
Check out a full list of the insider buys occurring this week by looking at the GuruFocus Insider Trades Page.
Try a free 7-day premium membership here.
Tessera Technologies (TSRA)
Over the past week there have been three directors of Tessera making notable buys back into the company. These three insiders made five separate buys, adding 628,500 shares to their stake.
Director Peter Feld made the largest transaction by making three buys and purchasing a total of 625,000. He purchased these shares in the price range of $18.44 to $18.93 per share. The price per share has dropped approximately -1.32%. Feld now owns 4.7 million shares of Tessera stock.
Director George Riedel bought 1,500 shares at $18.82 per share. This transaction cost the director a total of $28,230. Since his buy, the price per share has dropped approximately -1.7%. Riedel now owns at least 20,066 shares of company stock.
Director George Cwynar added 2,000 shares to his holdings at an average price of $18.49 per share. The transaction cost the director a total of $36,980. Since his buy, the price per share has increased 0.05%. Cwynar now holds on to 20,226 shares of company stock.
[/url]Tessera Technologies is a holding company with operating subsidiaries in two segments: Intellectual Property and DigitalOptics.
Tessera Technologies’ historical revenue and net income:
The analysis on Tessera Technologies reports that the company’s P/E ratio is at a 10-year high, its revenue has been in decline over the past five years, its dividend yield is at a 2-year high and that the company has no debt.
Tessera Technologies has a market cap of $996.9 million. Its shares are currently trading at a P/E ratio of 166.00, a P/S ratio of 4.70 and a P/B ratio of 1.70. The company’s dividend yield is currently at 2.20%.
There are currently four gurus that hold a position in TSRA.
Valeant Pharmaceuticals (VRX)
During the past week there have been two insiders that have made notable buys into Valeant Pharmaceuticals.
Director Ronald Farmer bought 2,500 shares on Aug. 28. The director bought these shares at an average price of $102.36 per share for a total transaction amount of $255,900. Since this buy, the price per share has dropped approximately -3.33%. Farmer now holds on to at least 26,057 shares of company stock.
Executive VP, General Counsel and Corporate Secretary Robert Chai-Onn purchased 5,032 shares on Aug. 23. The VP purchased these shares at $99.30 per share for a total transaction amount of $499,678. Since his buy the price per share has dropped approximately -0.35%. Chai-Onn now holds on to a total of 188,277 shares of company stock.
These buys came as the price per share hit a 10-year high.
Valeant Pharmaceuticals is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.
Valeant Pharmaceuticals’ historical revenue and net income:
The analysis on Valeant reports that the price is near a 10-year high, the P/E ratio is at a 10-year high, the company has issued $6.5 billion of debt over the past three years and that the company’s asset growth is faster than its revenue growth.
Valeant Pharmaceuticals has a market cap of $32.81 billion. Its shares are currently trading at around $98.68 with a P/E ratio of 1041.60, a P/S ratio of 7.50 and a P/B ratio of 5.20. The company had an annual average earnings growth of 4.2% over the past ten years.
There are currently 18 gurus that hold a position in Valeant Pharmaceuticals.
Multi-Color Corporation (LABL)
Over the past week two directors made buys into Multi-Color Corporation.
Director Ari Benacerraf bought 12,000 shares on Aug. 23. The director bought these shares at a price of $32.48 per share for a total transaction amount of $389,760. Since his buy, the price per share has dropped -3.33%.
Director Simon Roberts added a much smaller 2,400 shares to his stake at an average cost of $32.42 per share. This cost him a total of $77,808. Since his buy, the price per share has dropped -3.15%.
[/url]These insider buys were made as the company’s price hit a 10-year high.
The Company provides a wide range of products for the packaging needs of its customers and is a producer of high quality pressure sensitive, in-mold and heat transfer labels, and a major manufacturer of glue-applied and shrink sleeve labels.
Multi-Color’s historical revenue and net income:
The analysis on Multi-Color reports that company has issued $320.952 million of debt in the past three years, they have shown predictable revenue and earnings growth, the operating margin is expanding and their price is nearing a 10-year high.
The Peter Lynch Chart suggests that the company is currently overvalued:
Multi-Color has a market cap of $514.4 million. Its shares are currently trading at around $31.40 with a P/E ratio of 17.70, a P/S ratio of 0.80 and a P/B ratio of 1.90. The company had an annual average earnings growth of 14.3% over the past ten years.
GuruFocus rated Multi-Color the business predictability rank of 4-star.
Joel Greenblatt and Jim Simons hold a position in Multi-Color Corporation.
Independent Bank Group (IBTX)
Over the past week Independent Bank Group reported eight insider buys as coming from six different insiders. These buys come as the share price has taken a slight drop.
The insiders making buys consisted of Director William Fair, Director Stacy Smith, Executive VP and CFO Michelle Hickrox, Vice Chairman and CLO Brian Hobart, Director Brian Aynesworth III and President and COO Torry Berntsen.
These insiders bought a total of 28,718 shares of IBTX in the price range of $34.02 to $35.07, with an estimated average price of $34.49 per share. Since these buys the price per share has increased approximately 2.1%.
Director William Fair bought a total of 14,192 shares at an average price of $34.52 per share. These buys cost him a total of $491,960. Since his buys, the share price has increased
Independent Bank Group is a holding company for Independent Bank which provides a wide range of relationship-driven commercial banking products and services tailored to meet the needs of businesses, professionals and individuals. The company operates offices in Dallas/Fort Worth and the greater Austin area.
Independent Bank’s historical revenue and net income:
The company recently announced that they would be acquiring Live Oak State Bank.
The analysis on Independent Bank Group reports that the price is nearing a 52-week high and that the company has enough cash to cover all of its debt.
Independent Bank Group has a market cap of $411.8 million. Its shares are currently trading at around $34.12 with a P/E ratio of 13.90, a P/S ratio of 3.90 and a P/B ratio of 1.90.
Chuck Royce holds a stake in Independent Bank Group.
Check out a full list of the insider buys occurring this week by looking at the GuruFocus Insider Trades Page.
Try a free 7-day premium membership here.
